AngioDynamics Inc., whose products include radiofrequency ablation and irreversible electroporation resection systems, has appointed Jan Keltjens as president and CEO. Keltjens, an executive with more than 20 years of successful medical industry leadership experience, will take the reins effective March 1, 2009.  The 51-year-old Keltjens, will succeed Eamonn Hobbs, a cofounder of AngioDynamics who has led the company for the past 21 years. Hobbs will become vice chairman of the company's board of directors.</p><!--<p><br /></p> --><p>&ldquo;Jan's appointment is the culmination of an extensive search for the best candidate to build on the successes of Eamonn's founding leadership and take us to the next level in the company's growth and development,&rdquo; said Vincent Bucci, AngioDynamics' chairman of the board in a press statement. &ldquo;Eamonn built AngioDynamics into a $200-million enterprise, and we believe Jan is the right person to take us to the half-billion-dollar revenue level and beyond. Jan brings to the company extensive global operating and managerial experience, as well as very strong industry background and a continuous track record of success.&rdquo;</p><p>Keltjens comes to AngioDynamics after serving as president and CEO of CryoCath Technologies Inc. since early 2007. Based in Montreal, QC, Canada, the medical technology company is a leader in cryotherapy products for treating cardiac arrhythmias and was recently acquired by Medtronic Inc. He previously served in various leadership positions at Cordis, a Johnson & Johnson company, including his last position as worldwide general manager of Cordis Neurovascular. He first joined Cordis in 1995 as vice president and managing director responsible for international manufacturing and distribution operations, as well as research and development. He was promoted to vice president of European marketing and vice President of worldwide strategic marketing for Cordis Cardiology. Before joining Cordis, Keltjens led research and development departments at Unilever and was managing director of a group of small high-tech companies.</p><p>&ldquo;The Company's IRE technology has the potential to become a game-changing technology addressing significant unmet clinical needs in the oncology field, and I believe there are many more opportunities to consistently grow the Access, Peripheral Vascular and Oncology businesses,&rdquo; sais Keltjens. &ldquo;At the same time, a strong balance sheet presents more opportunities for growth through carefully targeted and well-executed acquisitions. &rdquo;</p><p>Hobbs said that Keltjens brings Angiodynamics a comprehensive understanding of the company's current markets. &ldquo;During his career, [he] has even managed an angiographic catheter product line. I look forward to working with Jan on a smooth transition of the CEO's responsibilities, as well as refining my ongoing role with the company in the development of markets for IRE technology,&rdquo; said Hobbs.</p><p>AngioDynamics Inc. devlops medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. In addition to radiofrequency ablation and irreversible electroporation resection systems, the company develops vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at <a href="http://www.angiodynamics.com" target="_blank">www.angiodynamics.com</a>.</p><p>&copy; 2009 Canon Communications LLC<a href="http://devicelink.com/mx/issuesupdate"><strong><br></strong></a></p></body></html>